Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scinopharm TaiwanTPE:1789 -0.50%73 PS Ratio is 5.01 as of Jul. 14, 2026, which is 26% below its 10-year median of 6.74. GuruFocus rates TPE:1789 with a GF Score™ of 73/100 and a GF Value™ of NT$27.31 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, Scinopharm Taiwan ranks worse than 74.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Scinopharm Taiwan's share price is NT$19.90.
Scinopharm Taiwan's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$3.98. Hence, Scinopharm Taiwan's PS Ratio for today is 5.01.
The historical rank and industry rank for Scinopharm Taiwan's PS Ratio or its related term are showing as below:
TPE:1789'
s PS Ratio Range Over the Past 10 Years
Min: 4.23 Med: 6.74 Max: 11.77
Current: 5
During the past 13 years, Scinopharm Taiwan's highest PS Ratio was 11.77. The lowest was 4.23. And the median was 6.74.
TPE:1789's PS Ratio is ranked worse than 74.03% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs TPE:1789: 5.00
Scinopharm Taiwan Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Scinopharm Taiwan was -7.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -2.10% per year.
During the past 13 years, Scinopharm Taiwan's highest 3-Year average Revenue per Share Growth Rate was 7.20% per year. The lowest was -10.40% per year. And the median was -2.40% per year.
Back to Basics: PS Ratio
Scinopharm Taiwan (TPE:1789) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Scinopharm Taiwan PS Ratio Related Terms
Scinopharm Taiwan PS Ratio Historical Data
* Premium members only.
The historical data trend for Scinopharm Taiwan's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scinopharm Taiwan PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's PS Ratio distribution charts can be found below:
* The bar in red indicates where Scinopharm Taiwan's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Scinopharm Taiwan's Share Price of today is NT$19.90. Scinopharm Taiwan's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Scinopharm Taiwan (TPE:1789) has a PS Ratio of 5.01 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Scinopharm Taiwan and its competitors. This is 26% below median its historical median of 6.74. Over the past decade, Scinopharm Taiwan's PS Ratio has ranged from 4.23 to 11.77. According to the industry distribution chart, Scinopharm Taiwan ranks #707 out of 955 companies in the Drug Manufacturers industry, placing it in the top 74%.
Is Scinopharm Taiwan's PS Ratio too high?
Scinopharm Taiwan's current PS Ratio of 5.01 is 26% below median its 10-year median of 6.74. Over the past 10 years, this metric has ranged from a low of 4.23 to a high of 11.77. The Drug Manufacturers industry median PS Ratio is 2.33. Scinopharm Taiwan's value of 5.01 is 115% above this industry median. Based on the distribution chart, Scinopharm Taiwan ranks #707 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scinopharm Taiwan has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Scinopharm Taiwan ranks #707 out of 955 companies for PS Ratio. This places Scinopharm Taiwan in the lower half of its industry. The industry median PS Ratio is 2.33. Scinopharm Taiwan's value of 5.01 is 115% above this benchmark. Historically, Scinopharm Taiwan's own PS Ratio has ranged from 4.23 to 11.77 over the past decade. While the company's 10-year median is 6.74 vs. the industry median of 2.33, Scinopharm Taiwan has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scinopharm Taiwan's current PS Ratio of 5.01 is 115% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Scinopharm Taiwan and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scinopharm Taiwan's current PS Ratio is 5.01, which is 26% below median its own 10-year median of 6.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.31, compared to a current price of NT$19.90 — trading 27.1% below its estimated fair value. The current PS Ratio is 5.01, which is 26% below median its 10-year median of 6.74 and 115% above the Drug Manufacturers industry median of 2.33. Scinopharm Taiwan's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current PS Ratio is 5.01 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?
Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued.
The current stock price of NT$19.90 is trading 27.1% below its estimated GF Value™ of NT$27.31.
GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.
Key valuation signals for TPE:1789:
PS Ratio: 5.01 (26% below median its 10-year median of 6.74)
GF Value™: NT$27.31 vs. price of NT$19.90 (27.1% below fair value)
Industry Position: 115% above the Drug Manufacturers median (#707 of 955)
No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
73GF Score
Get the complete analysis for TPE:1789
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1789 has been successfully added to your 
